Jianyun Yan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jianyun Yan has a total of 236 co-authors. Here are the top co-authors by number of shared publications:
An Chen
Department of Cardiology, Laboratory of Heart Center, Heart Center, Zhujiang Hospital, Southern Medical University, China; Guangdong Provincial Key Laboratory of Cardiac Function and Microcirculation, Guangdong Provincial Biomedical Engineering Technology Research Center for Cardiovascular Disease, Guangzhou, 510280, China
13 shared publicationsYining Li
Department of Cardiology, Laboratory of Heart Center, Heart Center, Zhujiang Hospital, Southern Medical University, China; Guangdong Provincial Key Laboratory of Cardiac Function and Microcirculation, Guangdong Provincial Biomedical Engineering Technology Research Center for Cardiovascular Disease, Guangzhou, 510280, China
13 shared publicationsXiaoyu Liu
Department of Cardiology, Laboratory of Heart Center, Heart Center, Zhujiang Hospital, Southern Medical University; Guangdong Provincial Key Laboratory of Cardiac Function and Microcirculation; Guangdong Provincial Biomedical Engineering Technology Research Center for Cardiovascular Disease; Sino-Japanese Cooperation Platform for Translational Research in Heart Failure, Guangzhou 510280, China
12 shared publicationsZirong Lan
Department of Cardiology, Laboratory of Heart Center, Heart Center, Zhujiang Hospital, Southern Medical University, China; Guangdong Provincial Key Laboratory of Cardiac Function and Microcirculation, Guangdong Provincial Biomedical Engineering Technology Research Center for Cardiovascular Disease, Guangzhou, 510280, China
12 shared publications- Lihe Lu
Department of Pathophysiolgy, Zhongshan Medical School, Sun Yat-Sen University, Guangzhou, China
10 shared publications Qingchun Liang
Department of Anesthesiology, The Third Affiliated Hospital Southern Medical University Guangzhou People's Republic of China
10 shared publications
Latest Publications
- 23 April 2026
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 251, 387-404
DECR1 degradation by ursolic acid alleviates vascular calcification through inhibition of NF-κB/NLRP3 signaling pathway
- 23 April 2026
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 251, 387-404
DECR1 degradation by ursolic acid alleviates vascular calcification through inhibition of NF-κB/NLRP3 signaling pathway
- Open Access
- 3 December 2025
- Published by Elsevier in Redox Biology
- Vol. 89, 103961
Ultrasmall Cu2−xSe nanoparticles alleviate vascular calcification through inhibiting oxidative stress and NF-κB/NLRP3-mediated inflammation
- 3 December 2025
- Published by Elsevier in Redox Biology
- Vol. 89, 103961
Open AccessUltrasmall Cu2−xSe nanoparticles alleviate vascular calcification through inhibiting oxidative stress and NF-κB/NLRP3-mediated inflammation
- 13 November 2025
- Published by Elsevier in European Journal of Pharmacology
- Vol. 1008, 178355
NF-κB/TOM6/PINK1-mediated mitophagy attenuates vascular calcification: Luteolin as a therapeutic modulator
- 13 November 2025
- Published by Elsevier in European Journal of Pharmacology
- Vol. 1008, 178355
NF-κB/TOM6/PINK1-mediated mitophagy attenuates vascular calcification: Luteolin as a therapeutic modulator
- 15 October 2025
- Published by Elsevier in Atherosclerosis
- Vol. 411, 120548
Alamandine suppresses vascular calcification through inhibition of ferroptosis
- 15 October 2025
- Published by Elsevier in Atherosclerosis
- Vol. 411, 120548
Alamandine suppresses vascular calcification through inhibition of ferroptosis
- 14 October 2025
- Published by Wolters Kluwer Health in Circulation
- Vol. 152 (15) , 1087-1108
TAX1BP3 Is a SUMOylated Nucleocytoplasmic Shuttling Protein and Protects Against Vascular Neointimal Hyperplasia
BACKGROUND: Neointimal hyperplasia is the major cause of significant vascular complications after arterial interventions. Despite the advancements in strategies such as drug-eluting stents to minimize neointimal hyperplasia, achieving consistently effective long-term outcomes remains a challenge. Protein-protein interactions mediated by PDZ (PSD-95, Discs-large, and ZO-1) domains are essential for numerous biological processes. However, little is known about the role of PDZ proteins in neointima formation. This study aims to explore the role of TAX1BP3 (Tax1 binding protein 3), a singular PDZ protein, in phenotypic switching of vascular smooth muscle cells (VSMCs) and its implication in neointimal hyperplasia. METHODS: Subcellular localization of TAX1BP3 was assessed in isolated VSMCs or arteries obtained from mice with neointima formation. TAX1BP3 mutants were constructed to study the role of SUMOylation on TAX1BP3 nucleocytoplasmic shuttling. VSMC-specific Tax1bp3 knockout mice were generated to determine the relevant phenotypes in a carotid artery wire injury model. RNA sequencing, assays for transposase-accessible chromatin using sequencing, computational prediction of complex structures, and coimmunoprecipitation were performed to elucidate the underlying molecular mechanisms. Adeno-associated virus-mediated Tax1bp3 gene delivery and nanoencapsulated-TAX1BP3 were employed to investigate the potential translational relevance. RESULTS: TAX1BP3 exhibited dynamic nucleocytoplasmic shuttling during phenotypic switching of VSMCs. TAX1BP3 is SUMOylated at K116, and its SUMOylation is essential for maintaining the nuclear localization of TAX1BP3. Deficiency of TAX1BP3 facilitated the transition from a contractile to a synthetic phenotype and aggravated neointima formation after vascular injury in mice. The integration of RNA sequencing and an assay for transposase-accessible chromatin using sequencing unveiled that TAX1BP3 primarily regulated the cell cycle progression and cell proliferation of VSMCs through YAP-TEAD transcription activity. The computational prediction of TAX1BP3/YAP1 complex structures and protein interaction–related experiments revealed that TAX1BP3 and TEAD1 compete for binding to YAP through its TEAD binding domain (BD) in a noncanonical PDZ manner. AAV-mediated Tax1bp3 gene delivery significantly attenuated postinjury neointima formation and the progression of atherosclerosis. Nanoencapsulated-TAX1BP3 administration effectively reduced VSMC phenotypic switching and neointimal hyperplasia. CONCLUSIONS: These results demonstrate that SUMOylation of TAX1BP3 at K116 enables its nucleocytoplasmic shuttling during phenotypic switching of VSMCs. TAX1BP3 competitively interacts with the YAP-TEAD complex in a noncanonical PDZ manner and exerts its protective role in vascular neointimal hyperplasia primarily through the regulation of cell proliferation.
- 14 October 2025
- Published by Wolters Kluwer Health in Circulation
- Vol. 152 (15) , 1087-1108
TAX1BP3 Is a SUMOylated Nucleocytoplasmic Shuttling Protein and Protects Against Vascular Neointimal Hyperplasia
BACKGROUND: Neointimal hyperplasia is the major cause of significant vascular complications after arterial interventions. Despite the advancements in strategies such as drug-eluting stents to minimize neointimal hyperplasia, achieving consistently effective long-term outcomes remains a challenge. Protein-protein interactions mediated by PDZ (PSD-95, Discs-large, and ZO-1) domains are essential for numerous biological processes. However, little is known about the role of PDZ proteins in neointima formation. This study aims to explore the role of TAX1BP3 (Tax1 binding protein 3), a singular PDZ protein, in phenotypic switching of vascular smooth muscle cells (VSMCs) and its implication in neointimal hyperplasia. METHODS: Subcellular localization of TAX1BP3 was assessed in isolated VSMCs or arteries obtained from mice with neointima formation. TAX1BP3 mutants were constructed to study the role of SUMOylation on TAX1BP3 nucleocytoplasmic shuttling. VSMC-specific Tax1bp3 knockout mice were generated to determine the relevant phenotypes in a carotid artery wire injury model. RNA sequencing, assays for transposase-accessible chromatin using sequencing, computational prediction of complex structures, and coimmunoprecipitation were performed to elucidate the underlying molecular mechanisms. Adeno-associated virus-mediated Tax1bp3 gene delivery and nanoencapsulated-TAX1BP3 were employed to investigate the potential translational relevance. RESULTS: TAX1BP3 exhibited dynamic nucleocytoplasmic shuttling during phenotypic switching of VSMCs. TAX1BP3 is SUMOylated at K116, and its SUMOylation is essential for maintaining the nuclear localization of TAX1BP3. Deficiency of TAX1BP3 facilitated the transition from a contractile to a synthetic phenotype and aggravated neointima formation after vascular injury in mice. The integration of RNA sequencing and an assay for transposase-accessible chromatin using sequencing unveiled that TAX1BP3 primarily regulated the cell cycle progression and cell proliferation of VSMCs through YAP-TEAD transcription activity. The computational prediction of TAX1BP3/YAP1 complex structures and protein interaction–related experiments revealed that TAX1BP3 and TEAD1 compete for binding to YAP through its TEAD binding domain (BD) in a noncanonical PDZ manner. AAV-mediated Tax1bp3 gene delivery significantly attenuated postinjury neointima formation and the progression of atherosclerosis. Nanoencapsulated-TAX1BP3 administration effectively reduced VSMC phenotypic switching and neointimal hyperplasia. CONCLUSIONS: These results demonstrate that SUMOylation of TAX1BP3 at K116 enables its nucleocytoplasmic shuttling during phenotypic switching of VSMCs. TAX1BP3 competitively interacts with the YAP-TEAD complex in a noncanonical PDZ manner and exerts its protective role in vascular neointimal hyperplasia primarily through the regulation of cell proliferation.
- 4 September 2025
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
NAMPT Is A Novel Inhibitor of Vascular Calcification in Chronic Kidney Disease
BACKGROUND: Vascular calcification is very common in patients with chronic kidney disease and contributes to the increased risk of cardiovascular events. NAMPT (nicotinamide phosphoribosyltransferase), the rate-limiting enzyme in the salvage pathway of nicotinamide adenine dinucleotide, has been shown to exert an antiaging effect on vascular smooth muscle cells. However, whether NAMPT is involved in the regulation of vascular calcification remains unclear. METHODS: ELISA, immunofluorescence, and Western blot were used to detect NAMPT levels in human blood and tissues. Alizarin red staining, calcium content assay, and microcomputed tomography were used to investigate the role of NAMPT in vascular calcification. Gene expression analysis and coimmunoprecipitation were performed to elucidate the underlying mechanism. RESULTS: ELISA, immunofluorescence, and Western blot showed that NAMPT levels were increased in the blood of patients with chronic kidney disease and human calcified arterial tissues. Alizarin red staining and calcium content assay revealed that pharmacological inhibition or knockdown of NAMPT exacerbated vascular smooth muscle cell calcification, whereas overexpression of NAMPT reduced mineral deposition under osteogenic conditions. Similarly, ex vivo studies revealed that NAMPT inhibited calcification of rat and human arterial rings. Moreover, administration of NAMPT inhibitor FK866 promoted aortic calcification of chronic kidney disease rats, and smooth muscle cell–specific NAMPT knockout mice exhibited aggravated aortic calcification. Furthermore, pharmacological inhibition and knockdown of SIRT1 (sirtuin 1) abrogated the inhibitory effect of NAMPT on vascular calcification. In addition, smooth muscle cell–specific SIRT1 deficiency abrogated the protective effect of recombinant NAMPT on mouse aortic calcification. Coimmunoprecipitation and immunofluorescence assay further revealed that NAMPT inhibited the acetylation of NICD (Notch intracellular domain) and reduced the expression of HES1 (hairy and enhancer of split-1) in a SIRT1-dependent pathway. CONCLUSIONS: Our study unveils that NAMPT could serve as a novel endogenous inhibitor of vascular calcification via modulation of SIRT1-mediated deacetylation of NICD.
- 4 September 2025
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
NAMPT Is A Novel Inhibitor of Vascular Calcification in Chronic Kidney Disease
BACKGROUND: Vascular calcification is very common in patients with chronic kidney disease and contributes to the increased risk of cardiovascular events. NAMPT (nicotinamide phosphoribosyltransferase), the rate-limiting enzyme in the salvage pathway of nicotinamide adenine dinucleotide, has been shown to exert an antiaging effect on vascular smooth muscle cells. However, whether NAMPT is involved in the regulation of vascular calcification remains unclear. METHODS: ELISA, immunofluorescence, and Western blot were used to detect NAMPT levels in human blood and tissues. Alizarin red staining, calcium content assay, and microcomputed tomography were used to investigate the role of NAMPT in vascular calcification. Gene expression analysis and coimmunoprecipitation were performed to elucidate the underlying mechanism. RESULTS: ELISA, immunofluorescence, and Western blot showed that NAMPT levels were increased in the blood of patients with chronic kidney disease and human calcified arterial tissues. Alizarin red staining and calcium content assay revealed that pharmacological inhibition or knockdown of NAMPT exacerbated vascular smooth muscle cell calcification, whereas overexpression of NAMPT reduced mineral deposition under osteogenic conditions. Similarly, ex vivo studies revealed that NAMPT inhibited calcification of rat and human arterial rings. Moreover, administration of NAMPT inhibitor FK866 promoted aortic calcification of chronic kidney disease rats, and smooth muscle cell–specific NAMPT knockout mice exhibited aggravated aortic calcification. Furthermore, pharmacological inhibition and knockdown of SIRT1 (sirtuin 1) abrogated the inhibitory effect of NAMPT on vascular calcification. In addition, smooth muscle cell–specific SIRT1 deficiency abrogated the protective effect of recombinant NAMPT on mouse aortic calcification. Coimmunoprecipitation and immunofluorescence assay further revealed that NAMPT inhibited the acetylation of NICD (Notch intracellular domain) and reduced the expression of HES1 (hairy and enhancer of split-1) in a SIRT1-dependent pathway. CONCLUSIONS: Our study unveils that NAMPT could serve as a novel endogenous inhibitor of vascular calcification via modulation of SIRT1-mediated deacetylation of NICD.
- 9 August 2025
- Published by Elsevier in International Journal of Cardiology
- Vol. 440, 133746
Genetic association between inflammatory factors and abdominal aortic calcification: Insights from a genome-wide association study
- 9 August 2025
- Published by Elsevier in International Journal of Cardiology
- Vol. 440, 133746
Genetic association between inflammatory factors and abdominal aortic calcification: Insights from a genome-wide association study
- 27 June 2025
- Published by Wolters Kluwer Health in Circulation Research
E3 Ubiquitin Ligase TRIM16-Mediated K63-linked Ubiquitination of DAB2 Enhances Integrin β1 Endocytosis to Facilitate Vascular Calcification
BACKGROUND: Vascular calcification is highly prevalent in patients with chronic kidney disease (CKD), and the underlying mechanisms remain elusive. Several studies have indicated an important role of protein ubiquitination in vascular calcification. However, the role of E3 ubiquitin ligases in vascular calcification remains poorly understood. METHODS: Calcification of vascular smooth muscle cells (VSMCs) was induced by high phosphate. CKD mouse model was induced by an adenine diet, and CKD rat model was established using 5/6 nephrectomy method. Adenovirus, siRNA, adeno-associated virus, and smooth muscle cell–specific TRIM16 (tripartite motif 16) knockout mice were used to investigate the role of TRIM16 in vascular calcification. Immunoprecipitation–mass spectrometry, and ubiquitination assay were used to dissect how TRIM16 regulates vascular calcification. RESULTS: Bioinformatic analysis suggested that E3 ubiquitin TRIM16 could be a key modulator of vascular calcification. TRIM16 expression was increased during vascular calcification. Overexpression of TRIM16 exacerbated VSMC calcification and aortic calcification of CKD rats. By contrast, the knockdown of TRIM16 alleviated VSMC calcification and aortic calcification in CKD rats. Moreover, the deletion of TRIM16 inhibited VSMC calcification and aortic calcification in VitD3-overloaded mice and CKD mice. Mechanistically, immunoprecipitation–mass spectrometry revealed that DAB2 (disabled homolog 2) was the potential downstream target of TRIM16. Coimmunoprecipitation showed that the SPRY domain of TRIM16 interacted with the proline-rich domain of DAB2. Moreover, ubiquitination assay revealed that the SPRY domain of TRIM16 is required for TRIM16-mediated K63-linked ubiquitination of DAB2 at K656 residue. Of note, the knockdown of DAB2 inhibited TRIM16-induced VSMC calcification. Furthermore, knockdown of DAB2 antagonized endocytosis of integrin β1 and subsequent activation of FAK (focal adhesion kinase)-STAT3 (signal transduction and transcriptional activation factor 3) signaling induced by overexpression of TRIM16. CONCLUSIONS: Our study for the first time demonstrates that E3 ubiquitin ligase TRIM16 catalyzes K63-ubiquitination of the endocytic adaptor DAB2, leading to endocytosis of integrin β1 and activation of FAK-STAT3 signaling, and subsequently exacerbates vascular calcification, suggesting that TRIM16-DAB2 axis is a promising therapeutic target for vascular calcification.
- 27 June 2025
- Published by Wolters Kluwer Health in Circulation Research
E3 Ubiquitin Ligase TRIM16-Mediated K63-linked Ubiquitination of DAB2 Enhances Integrin β1 Endocytosis to Facilitate Vascular Calcification
BACKGROUND: Vascular calcification is highly prevalent in patients with chronic kidney disease (CKD), and the underlying mechanisms remain elusive. Several studies have indicated an important role of protein ubiquitination in vascular calcification. However, the role of E3 ubiquitin ligases in vascular calcification remains poorly understood. METHODS: Calcification of vascular smooth muscle cells (VSMCs) was induced by high phosphate. CKD mouse model was induced by an adenine diet, and CKD rat model was established using 5/6 nephrectomy method. Adenovirus, siRNA, adeno-associated virus, and smooth muscle cell–specific TRIM16 (tripartite motif 16) knockout mice were used to investigate the role of TRIM16 in vascular calcification. Immunoprecipitation–mass spectrometry, and ubiquitination assay were used to dissect how TRIM16 regulates vascular calcification. RESULTS: Bioinformatic analysis suggested that E3 ubiquitin TRIM16 could be a key modulator of vascular calcification. TRIM16 expression was increased during vascular calcification. Overexpression of TRIM16 exacerbated VSMC calcification and aortic calcification of CKD rats. By contrast, the knockdown of TRIM16 alleviated VSMC calcification and aortic calcification in CKD rats. Moreover, the deletion of TRIM16 inhibited VSMC calcification and aortic calcification in VitD3-overloaded mice and CKD mice. Mechanistically, immunoprecipitation–mass spectrometry revealed that DAB2 (disabled homolog 2) was the potential downstream target of TRIM16. Coimmunoprecipitation showed that the SPRY domain of TRIM16 interacted with the proline-rich domain of DAB2. Moreover, ubiquitination assay revealed that the SPRY domain of TRIM16 is required for TRIM16-mediated K63-linked ubiquitination of DAB2 at K656 residue. Of note, the knockdown of DAB2 inhibited TRIM16-induced VSMC calcification. Furthermore, knockdown of DAB2 antagonized endocytosis of integrin β1 and subsequent activation of FAK (focal adhesion kinase)-STAT3 (signal transduction and transcriptional activation factor 3) signaling induced by overexpression of TRIM16. CONCLUSIONS: Our study for the first time demonstrates that E3 ubiquitin ligase TRIM16 catalyzes K63-ubiquitination of the endocytic adaptor DAB2, leading to endocytosis of integrin β1 and activation of FAK-STAT3 signaling, and subsequently exacerbates vascular calcification, suggesting that TRIM16-DAB2 axis is a promising therapeutic target for vascular calcification.
- 28 May 2025
- Published by Wiley in The FASEB Journal
- Vol. 39 (11) , e70677
GDF11 Alleviates Vascular Calcification in VitD 3 ‐Overloaded Mice Through Inhibition of Inflammatory NF‐κB Signal
Vascular calcification, an age‐associated disorder, is a highly regulated biological process similar to bone formation. Growth differentiation factor 11 (GDF11), a secreted member of the transforming growth factor beta (TGF‐β) superfamily, has been shown to act as an anti‐aging factor in the brain, heart, skin, and skeletal muscle. Nevertheless, whether GDF11 affects vascular calcification and the underlying mechanisms remain unclear. In the present study, beta‐glycerophosphate and calcium chloride‐induced calcification of vascular smooth muscle cells (VSMCs) and a VitD 3 ‐overloaded mouse model were used to investigate the role of GDF11 in vascular calcification. Our results revealed that the knockdown of GDF11 by siRNA promoted the calcification of rat VSMCs, whereas GDF11 treatment significantly reduced the calcification of human and rat VSMCs in vitro, as detected by alizarin red staining and calcium content assay. Similarly, GDF11 treatment reduced the expression of bone‐related molecules including Runt‐related transcription factor 2 (Runx2) and bone morphogenetic protein‐2 (BMP2). Furthermore, ex vivo and in vivo studies confirmed the inhibitory effect of GDF11 on vascular calcification. Mechanistically, GDF11 treatment reduced the levels of NF‐κB signaling molecules including NLRP3, phosphorylated p65, IL‐6, and IL‐1β in VSMCs. Additionally, GDF11 siRNA‐induced VSMC calcification was repressed by NF‐κB inhibitor PDTC treatment. Taken together, these findings suggest that GDF11 alleviates vascular calcification through inhibiting the NF‐κB signal. Modulation of GDF11 may represent a therapeutic strategy for vascular calcification.
- 28 May 2025
- Published by Wiley in The FASEB Journal
- Vol. 39 (11) , e70677
GDF11 Alleviates Vascular Calcification in VitD 3 ‐Overloaded Mice Through Inhibition of Inflammatory NF‐κB Signal
Vascular calcification, an age‐associated disorder, is a highly regulated biological process similar to bone formation. Growth differentiation factor 11 (GDF11), a secreted member of the transforming growth factor beta (TGF‐β) superfamily, has been shown to act as an anti‐aging factor in the brain, heart, skin, and skeletal muscle. Nevertheless, whether GDF11 affects vascular calcification and the underlying mechanisms remain unclear. In the present study, beta‐glycerophosphate and calcium chloride‐induced calcification of vascular smooth muscle cells (VSMCs) and a VitD 3 ‐overloaded mouse model were used to investigate the role of GDF11 in vascular calcification. Our results revealed that the knockdown of GDF11 by siRNA promoted the calcification of rat VSMCs, whereas GDF11 treatment significantly reduced the calcification of human and rat VSMCs in vitro, as detected by alizarin red staining and calcium content assay. Similarly, GDF11 treatment reduced the expression of bone‐related molecules including Runt‐related transcription factor 2 (Runx2) and bone morphogenetic protein‐2 (BMP2). Furthermore, ex vivo and in vivo studies confirmed the inhibitory effect of GDF11 on vascular calcification. Mechanistically, GDF11 treatment reduced the levels of NF‐κB signaling molecules including NLRP3, phosphorylated p65, IL‐6, and IL‐1β in VSMCs. Additionally, GDF11 siRNA‐induced VSMC calcification was repressed by NF‐κB inhibitor PDTC treatment. Taken together, these findings suggest that GDF11 alleviates vascular calcification through inhibiting the NF‐κB signal. Modulation of GDF11 may represent a therapeutic strategy for vascular calcification.